DBV Technologies announces filing and validation of marketing authorization application for Viaskin™ Peanut by European Medicines Agency
- 17 November 2020
- News
DBV Technologies, a biopharmaceutical company and Corporate Member of the Campaign, announced on November 5 that its product Viaskin™ Peanut (DBV712) has been validated by the European Medicines Agency (EMA). The validation confirms that the submission is sufficiently complete to begin the formal review process for the investigational non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4 to 11 years.
To read the full press release, please go here
